(4-cyano-phenylamino)-{3-ethoxy-2-fluoro-5-[(R)-tetrahydro-furan-3-yloxy]-phenyl}-acetic acid ethyl ester | 376601-45-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (4-cyano-phenylamino)-{3-ethoxy-2-fluoro-5-[(R)-tetrahydro-furan-3-yloxy]-phenyl}-acetic acid ethyl ester
• 英文别名: (RS)-(4-cyano-phenylamino)-[5-ethoxy-2-fluoro-3-[(R)-tetrahydro-furan-3-yloxy]-phenyl]-acetic acid ethyl ester；ethyl 2-(4-cyanoanilino)-2-[5-ethoxy-2-fluoro-3-[(3R)-oxolan-3-yl]oxyphenyl]acetate
• CAS: 376601-45-5
• 化学式: C₂₃H₂₅FN₂O₅
• 分子量: 428.46
• InChiKey: WUONUGMJEKHNAL-PLEWWHCXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  31
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  89.8
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (4-cyano-phenylamino)-{3-ethoxy-2-fluoro-5-[(R)-tetrahydro-furan-3-yloxy]-phenyl}-acetic acid ethyl ester 在 盐酸 、 lithium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 氯仿 为溶剂， 反应 4.25h， 生成 (R)-(4-carbamimidoyl-phenylamino)-[5-ethoxy-2-fluoro-3-[(R)-tetrahydro-furan-3-yloxy]-phenyl]-acetic acid
  参考文献：
  名称：

  Dose-dependent antithrombotic activity of an orally active tissue factor/factor VIIa inhibitor without concomitant enhancement of bleeding propensity

  摘要：

  The discovery of a highly potent and selective tissue factor/factor VIIa inhibitor is described. Upon oral administration of its double prodrug in the guinea pig, a dose-dependent antithrombotic effect is observed in an established model of arterial thrombosis without prolonging bleeding time. The pharmacodynamic properties of this selective inhibitor are compared to the behaviour of a mixed factor VIIa/factor Xa inhibitor. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.03.042
• 作为产物：
  描述：

  4-氟苯乙醚 在 咪唑 、 正丁基锂 、 五甲基二乙烯三胺 、 三氟化硼乙醚 、 水 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 乙醇 、 正己烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 (4-cyano-phenylamino)-{3-ethoxy-2-fluoro-5-[(R)-tetrahydro-furan-3-yloxy]-phenyl}-acetic acid ethyl ester
  参考文献：
  名称：

  Dose-dependent antithrombotic activity of an orally active tissue factor/factor VIIa inhibitor without concomitant enhancement of bleeding propensity

  摘要：

  The discovery of a highly potent and selective tissue factor/factor VIIa inhibitor is described. Upon oral administration of its double prodrug in the guinea pig, a dose-dependent antithrombotic effect is observed in an established model of arterial thrombosis without prolonging bleeding time. The pharmacodynamic properties of this selective inhibitor are compared to the behaviour of a mixed factor VIIa/factor Xa inhibitor. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.03.042

文献信息

• N-(4-carbamimidoyl-phenyl)-glycine derivatives
  申请人：——

  公开号：US20020004608A1

  公开（公告）日：2002-01-10

  N-(4-carbamimidoyl-phenyl)-glycine derivatives have the formula: 1 wherein X and R 1 to R 5 are as defined herein, and includes hydrates or solvates and/or physiologically acceptable salts thereof and/or physiologically acceptable esters thereof.

  N-(4-羰基苄基)-甘氨酸衍生物的化学式为： 其中X和R1至R5如本文所定义，并包括其水合物或溶剂合物和/或其生理上可接受的盐和/或其生理上可接受的酯。
• [EN] PHENYLGLYCINE DERIVATIVES<br/>[FR] DERIVES DE PHENYLGLYCINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2001090051A1

  公开（公告）日：2001-11-29

  The invention is concerned with novel N-(4-carbamimidoyl-phenyl)-glycine derivatives of the formula (I) wherein X and R1 to R5 are as defined in the description and in the claims, as well as hydrates or solvates and/or physiologically acceptable salts thereof and/or physiologically acceptable esters thereof.

  本发明涉及公式（I）中的新型N-（4-氨基甲酰基苯基）-甘氨酸衍生物，其中X和R1到R5如说明书和权利要求中所定义，以及其水合物或溶剂化物和/或生理上可接受的盐和/或生理上可接受的酯。
• PHENYLGLYCINE DERIVATIVES
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1289939A1

  公开（公告）日：2003-03-12
• US6548694B2
  申请人：——

  公开号：US6548694B2

  公开（公告）日：2003-04-15
• Dose-dependent antithrombotic activity of an orally active tissue factor/factor VIIa inhibitor without concomitant enhancement of bleeding propensity
  作者：Katrin Groebke Zbinden、David W. Banner、Kurt Hilpert、Jacques Himber、Thierry Lavé、Markus A. Riederer、Martin Stahl、Thomas B. Tschopp、Ulrike Obst-Sander

  DOI：10.1016/j.bmc.2006.03.042

  日期：2006.8

  The discovery of a highly potent and selective tissue factor/factor VIIa inhibitor is described. Upon oral administration of its double prodrug in the guinea pig, a dose-dependent antithrombotic effect is observed in an established model of arterial thrombosis without prolonging bleeding time. The pharmacodynamic properties of this selective inhibitor are compared to the behaviour of a mixed factor VIIa/factor Xa inhibitor. (c) 2006 Elsevier Ltd. All rights reserved.